Wallstent endovascular prosthesis for the treatment of superior vena cava syndrome

Sasano, Susumu; Onuki, Takamasa; Mae, Masahiro; Oyama, Kunihiro; Sakuraba, Minoru; Nitta, Sumio

doi:10.1007/bf02913595

Cited by 13 publications

(12 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, SVCO was always improved by vascular stenting with high complete response rates (75% in the present study) as reported before [15], while response to chemotherapy or radiotherapy is frequently incomplete (78% in the present study, 31.3–63% in the literature [22]). Furthermore, an advantage for vascular stenting in the quickness of symptom relief is now demonstrated (24–72 h) [15, 16, 19, 23, 26, 27]. The fastness of symptom relief is of a great importance for patients whose life expectancy is severely curtailed.…”

Section: Discussionmentioning

confidence: 99%

“…Since the early 90s, stent placement was used especially after failure of the first-choice treatment (radiotherapy and/or chemotherapy) [6, 8, 10, 11, 14, 21, 26, 27]. In few cases, the time of vascular stenting is not clearly known [16, 23]. All of these studies investigated the efficacy of SVCO in the setting of both small-cell lung cancer (SCLC) and NSCLC, but none reported results separately by histological type.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Vascular Stenting for Palliation of Superior Vena cava Obstruction in Non-Small-Cell Lung Cancer Patients: A Future ‘Standard’ Procedure?

et al. 2004

View full text Add to dashboard Cite

Background: Stenting is a relatively new option in the management of superior vena cava obstruction (SVCO), but available data often concern non-malignant and/or various malignant diseases. Objective: The aim of this study was to assess the efficacy of vascular stenting as a first-choice treatment in SVCO in the exclusive setting of NSCLC. Patients and Methods: Retrospective study of NSCLC patients with SVCO treated in the past year. Demographic data, disease characteristics, etiologic and palliative treatment (use of vascular stenting) were recorded as well as treatment outcome and survival. Results: 17 patients were recruited. Eight had vascular stenting while 9 did not. Except for stenting, there was no difference between the two groups (median age 54 years; 80% men; 53% stage IIIB and 47% stage IV). Stenting (median length 60 mm) achieved complete resolution of SVCO more frequently (75 vs. 25%, p = 0.05) and faster (2 vs. 21 days, p = 0.002) without immediate or delayed complication. All patients with stents received anticoagulation therapy. Relapse rate after complete response (33 g, 50%, p = 0.6) was lower and time to relapse (6.5 g, 2 months) was longer for patients undergoing stenting, without reaching statistical significance. Median overall survival was not statistically different (8 and 5 months, p = 0.06). Conclusions: This study demonstrated the effectiveness of vascular stenting for SVCO in NSCLC patients. The high response rate, quick effect and safety of vascular stenting make this palliative treatment a candidate as a potential standard procedure. The results, however, must be confirmed in a prospective randomized trial including quality of life assessment.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Vascular Stenting for Palliation of Superior Vena cava Obstruction in Non-Small-Cell Lung Cancer Patients: A Future ‘Standard’ Procedure?

et al. 2004

View full text Add to dashboard Cite

show abstract

“…On the other hand, based on data from 20 articles [8,9,10,11,12,13,14,15,16, 18,20,21,22,23,24,25,27,28,29,30] regarding the type of stents placed, 233 (48%) stents were polymeric, 178 (37%) were metallic and 75 (15%) were hybrid. In the remaining three studies [17, 19, 26], a combination of metallic and polymeric and hybrid and metallic stents was used, but the exact number of each subcategory was not specified.…”

Section: Resultsmentioning

confidence: 99%

“…Out of the 23 reviewed papers [8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30], 3 papers [20, 22, 28] enrolled patients with malignant disease (primary or secondary), 12 papers [8,9,10,11,12,13, 15, 18, 19, 23, 25, 29] enrolled patients with benign disorder, while the remaining studies [14, 16, 17, 21, 24, 26, 27, 30] consisted of a mixed (malignant and benign) patient population. In total, the indication of airway stenting was malignancy and benign disease in 45% (224/501) and 55% (277/501) of included patients, respectively.…”

Section: Resultsmentioning

confidence: 99%

“…Out of the 864 initially retrieved papers, 23 articles, involving 501 patients (range: 1–82 patients, median: 15) with airway stents, fulfilled our inclusion criteria. To be precise, we reviewed four case reports, four case series and fifteen cohorts [8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30]. Characteristics and outcome data of the eligible reports are depicted in detail in online supplementary tables 1 and 2 (www.karger.com?doi=10.1159/213244).…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Infections Related to Airway Stenting: A Systematic Review

Agrafiotis

Siempos

Falagas³

2009

Respiration

View full text Add to dashboard Cite

Background: Airway stenting is nowadays an established method for the palliative and/or curative treatment of central airways obstruction. However, complications related to the use of airway stents have been reported. Objective: We endeavored to systematically evaluate the currently available evidence regarding the infections associated with airway stenting. Methods: We independently searched in PubMed for relevant reports. We considered articles which reported on clinical infections related to airway stenting. A case was identified as stent-associated respiratory tract infection (SARTI) according to the authors of the individual papers, based on clinical findings with or without radiological or microbiological confirmation. Results: Twenty-three articles (19 cohorts/case series and 4 case reports), involving 501 patients with airway stents, were included. The indication for airway stenting was malignancy and benign disease in 45 and 55% of the included patients, respectively. Ninety-three (19%) out of the 501 stented patients experienced SARTI. Pneumonia was the most common type of SARTI (47%), followed by bronchial infection (24%), cavitary pneumonia/lung abscess and intraluminal fungus ball. Staphylococcus aureus (39%) and Pseudomonas aeruginosa (28%) were the most commonly identified pathogens. Twenty-six (68%) out of the 38 patients with SARTI, for whom outcome data were available, died. Conclusion: The accumulated and evaluated evidence suggests that SARTI probably involves 1 in 5 patients with airway stent. Although the possibility of SARTI should not discourage the interventional pneumologists from inserting airway stents, the data seem to underline the urgent need for establishing a consensus definition and diagnostic criteria for SARTI.

show abstract

Endovascular Stenting in Superior Vena Cava Syndrome: A Systematic Review and Meta-analysis

Aung

Khan

Williams

et al. 2022

Cardiovasc Intervent Radiol

View full text Add to dashboard Cite

Purpose Endovascular stenting has been used to manage superior vena cava syndrome for several decades and has become standard firstline practice. This study aims to investigate the outcomes of endovascular stenting in the management of superior vena cava syndrome (SVCS). Methods MEDLINE, EMBASE and PUBMED online databases were searched, with studies involving more than ten adult patients included. Studies identified spanned 27 years, from 1993 to 2020. Meta-analyses were performed based on Clopper–Pearson estimation. Results Fifty-four studies were identified, for a total of 2249 patients, of which 2015 had malignant SVCS and 222 benign SVCS. Pooled technical success and clinical success rates were 96.8% (95% CI 96.0–97.5%) and 92.8% (95% CI 91.7–93.8%). Technical success and clinical success rates for studies investigating benign SVCS alone were identical at 88.8% (95% CI 83.0–93.1%). Pooled patency remained above 90% for the first year. Average complication and re-intervention rates were 5.78% (SD = 9.3182) and 9.11% (SD = 11.190). Conclusions This review confirms the effectiveness of endovascular stenting in managing SVCS. Further directions of research may include specific outcomes of endovascular stenting in benign SVCS, and the impact of procedural characteristics, such as the use of anticoagulation and type of stent used, on outcomes. Level of Evidence Level III, systematic review of retrospective cohort studies.

show abstract

Wallstent endovascular prosthesis for the treatment of superior vena cava syndrome

Abstract: Implantation of the self-expanding Wallstent endovascular prosthesis for malignant superior vena cava syndrome provides rapid symptomatic relief and improves the patient's quality of life.

Cited by 13 publications

References 21 publications

Vascular Stenting for Palliation of Superior Vena cava Obstruction in Non-Small-Cell Lung Cancer Patients: A Future ‘Standard’ Procedure?

Vascular Stenting for Palliation of Superior Vena cava Obstruction in Non-Small-Cell Lung Cancer Patients: A Future ‘Standard’ Procedure?

Infections Related to Airway Stenting: A Systematic Review

Endovascular Stenting in Superior Vena Cava Syndrome: A Systematic Review and Meta-analysis

Contact Info

Product

Resources

About